Wipe sampling locations should be based on identifying drug preparation, administration and disposal areas with potential for trace contamination. USP <800> recommends, at a minimum, the following locations:
– Interior of the containment primary engineering control (C-PEC) (eg, biological safety cabinet or containment ventilated enclosure)
– Pass-through chambers
– Surfaces in staging or work areas near the C-PEC
– Areas adjacent to C-PECs (eg, floors directly under the C-PEC, staging and dispensing spaces)
– Areas immediately outside the HD buffer room or the containment segregated compounding area (C-SCA)

References:
USP <800>
FIP 2025 surface sampling poster
https://www.cdc.gov/niosh/healthcare/hazardous-drugs/hazardous-drugs-resources.html                                                 Arnold S, Jeronimo M, Astrakianakis G, et al. Developing wipe sampling strategy guidance for assessing environmental contamination of antineoplastic drugs. Journal of Oncology Pharmacy Practice. 2022;29(8):1816-1824. doi:10.1177/10781552221118535

Yes. While HD compounding occurs in the pharmacy, contamination risks extend into clinic and patient care areas where drugs are administered and disposed of. Nurses and other clinical staff may be exposed to HD residues during infusion, patient handling, and waste management. Sampling should also include HD delivery bin, counter in the nursing area, infusion pump in the patient room, keyboard of computer, and bathroom.

References:
USP <800>
FIP 2025 surface sampling poster
https://www.cdc.gov/niosh/healthcare/hazardous-drugs/hazardous-drugs-resources.html                                                 Arnold S, Jeronimo M, Astrakianakis G, et al. Developing wipe sampling strategy guidance for assessing environmental contamination of antineoplastic drugs. Journal of Oncology Pharmacy Practice. 2022;29(8):1816-1824. doi:10.1177/10781552221118535

Quantitative methods provide precise measurements (ng/cm² or ng/225 cm²), offering clear advantages over qualitative testing, which only indicates whether contamination is present or not (learn more here). We offer among the lowest limits of detection (LODs) in the industry, allowing us to identify even the smallest traces of contamination that others may miss. Key benefits include:
– The ability to track contamination trends across time and locations
– Measurable thresholds for evaluating cleaning effectiveness
– Data-driven insights to guide corrective actions and improve safety

Results are provided through our secure online portal, where you can perform trend analysis and compare data over time. You will also receive a detailed report by email. Turn around time is 2-3 weeks. If contamination is detected, our experts will provide tailored recommendations and guidance to help reduce exposure levels. You can rely on us to support you every step of the way.

Yes. 5-FU and Methotrexate, known as common markers, can be tested through stand-alone drug analysis. Your choice should be guided by the drugs you most frequently compound. We offer flexible options to detect 1, 11, or 21 hazardous drugs (HDs) on the same swab, providing one of the most cost-efficient solutions in the industry. Prices starts at $145 USD/swab or $195 CAN/swab. Reach out to learn more about our exclusive savings on subscription plan.

You will receive everything required to perform the sampling on your own, along with a detailed sampling procedure. We also offer a quick Teams onboarding session to ensure you feel confident carrying out the process. Each kits includes:
– Plastic tubes and caps
– Trays (to hold the plastic tubes)
– Sterile water plastic ampoules (3mL)
– Return parcel with prepaid label
– Adhesive labels
– Filter papers
– Templates

Yes. We offer home surface wipe-sampling to screen for trace residues of hazardous (antineoplastic) medications on frequently touched household surfaces. This service is designed for patients on chemotherapy, family caregivers, and home-care teams who want added reassurance and guidance on safe handling